ARYA Share Price | Nautilus Biotechnology, Inc. Stock Analysis & Recommendation

Q: How big is Nautilus Biotechnology, Inc.?

Market Cap: As of Jun 18, Nautilus Biotechnology, Inc. has a market capitalization of 88.38 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Nautilus Biotechnology, Inc. reported net sales of 0.00 million and a net profit of -68.66 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 208.73 million and total assets of 242.74 million.

Q: What does Nautilus Biotechnology, Inc. do?

Overview: Nautilus Biotechnology, Inc. is a blank check company focused on effecting business combinations in the healthcare industry, particularly within the life sciences and medical technology sectors, and operates in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.Financial Snapshot: Net Profit: -17 Million (Quarterly Results - Mar 2025) Market Cap: USD 88.38 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.69 Return on Equity: -35.31% Price to Book: 0.45 Contact Details: Address: 51 Astor Place, 10Th Floor, NEW YORK NY: 10003 Tel: 1 212 2842300

Q: Is Nautilus Biotechnology, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Nautilus Biotechnology, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis. The RSI shows bearish momentum weekly while being bullish monthly. Moving averages indicate a mildly bearish trend on a daily basis. Overall, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -56.61% versus the S&P 500's 12.22%, and a one-year return of -74.60% compared to 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

154.33 k

Shareholding (Sep 2025)

FII

0.79%

Held by 26 FIIs

DII

73.33%

Held by 11 DIIs

Promoter

21.03%

How big is Nautilus Biotechnology, Inc.?

22-Jun-2025

As of Jun 18, Nautilus Biotechnology, Inc. has a market capitalization of 88.38 million, with net sales of 0.00 million and a net profit of -68.66 million over the latest four quarters. The company reported shareholder's funds of 208.73 million and total assets of 242.74 million as of Dec 24.

View full answer

What does Nautilus Biotechnology, Inc. do?

22-Jun-2025

Nautilus Biotechnology, Inc. is a blank check company targeting business combinations in the healthcare sector, particularly in life sciences and medical technology. As of March 2025, it has a market cap of $88.38 million and reported a net profit loss of $17 million.

View full answer

Is Nautilus Biotechnology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Nautilus Biotechnology, Inc. shows a mildly bearish trend, with mixed technical indicators and significant underperformance, having a year-to-date return of -56.61% compared to the S&P 500's 12.22%.

View full answer

Compare Nautilus Biotechnology, Inc. with Similar Stocks

iTeos Therapeutics, Inc.Mineralys Therapeutics, Inc.Agenus, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 275 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.75

Return on Equity

-37.14%

Price to Book

1.63

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

34.44%

6 Months

157.75%

1 Year

19.41%

2 Years

-23.97%

3 Years

0.5%

4 Years

-47.81%

5 Years

-81.89%

Nautilus Biotechnology, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-239.19%

EBIT to Interest (avg)

-68.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.69

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

49.85%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.50

EV to EBIT

0.48

EV to EBITDA

0.56

EV to Capital Employed

-0.63

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-35.31%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 19 Schemes (4.85%)

Foreign Institutions

Held by 26 Foreign Institutions (0.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 17.07% vs -3.14% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.90",
          "val2": "-17.50",
          "chgp": "20.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.60",
          "val2": "-16.40",
          "chgp": "17.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.15% vs -10.02% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-75.10",
          "val2": "-70.40",
          "chgp": "-6.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.80",
          "val2": "-63.70",
          "chgp": "-11.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-13.90

-17.50

20.57%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-13.60

-16.40

17.07%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 17.07% vs -3.14% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-75.10

-70.40

-6.68%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-70.80

-63.70

-11.15%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.15% vs -10.02% in Dec 2023

All Annual Results

Company CV

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

Pharmaceuticals & Biotechnology

ARYA Sciences Acquisition Corp III is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It intends to focus on entities operating in the healthcare industry, particularly the life sciences and medical technology sectors. It has not commenced any operations.

Company Coordinates

Company Details

51 Astor Place, 10Th Floor , NEW YORK NY : 10003

Tel: 1 212 2842300

Registrar Details

Nautilus Biotechnology, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Nautilus Biotechnology, Inc.?

Watch in Real-Time

What does Nautilus Biotechnology, Inc. do?

Is Nautilus Biotechnology, Inc. technically bullish or bearish?

Compare Nautilus Biotechnology, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Nautilus Biotechnology, Inc.

Company Coordinates